Jefferies Group LLC Exelixis, Inc. Call Options Transaction History

Jefferies Group LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	SELL	$17.44 - $23.16 $113,360 - $150,540	-6,500 Closed	0 $0
Q1 2022 Sep 21, 2023	BUY	$17.03 - $22.67 $110,695 - $147,355	6,500 New	6,500 $147,000
Q1 2022 May 16, 2022	BUY	$17.03 - $22.67 $110,695 - $147,355	6,500 New	6,500 $147,000
Q1 2020 May 15, 2020	SELL	$14.46 - $21.8 $1.08 Million - $1.64 Million	-75,000 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$15.15 - $18.89 $871,125 - $1.09 Million	57,500 Added 328.57%	75,000 $1.32 Million
Q2 2019 Aug 14, 2019	SELL	$18.93 - $24.75 $2.99 Million - $3.92 Million	-158,200 Reduced 90.04%	17,500 $374,000
Q4 2018 Feb 14, 2019	BUY	$13.65 - $21.8 $1.44 Million - $2.3 Million	105,700 Added 151.0%	175,700 $3.46 Million
Q3 2018 Nov 14, 2018	BUY	$15.87 - $22.4 $317,400 - $448,000	20,000 Added 40.0%	70,000 $1.24 Million
Q2 2018 Aug 14, 2018	BUY	$18.56 - $22.45 $927,999 - $1.12 Million	50,000 New	50,000 $1.08 Million

500

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.1B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.